Financial Performance - Revenue for Q3 2025 was $377.4 million, representing a 20% increase year-over-year[7] - Adjusted EBITDA for the quarter was $27.3 million, compared to $23.0 million in the prior year period[7] - Net income for the quarter was $9.6 million, a significant improvement from a net loss of $105.8 million in the prior-year period[7] - Revenues for the three months ended September 30, 2025, were $377,427,000, a decrease of 16.5% compared to $314,393,000 in the same period of 2024[26] - Operating income for the three months ended September 30, 2025, was $16,354,000, a significant recovery from an operating loss of $104,613,000 in the same period of 2024[26] - Net income attributable to Guardian Pharmacy Services, Inc. for the nine months ended September 30, 2025, was $28,296,000, compared to a net loss of $121,990,000 in 2024[26] - Adjusted EBITDA for the nine months ended September 30, 2025, was $75,659,000, up from $64,944,000 in 2024, indicating a growth of 16.5%[31] - The company reported a net income margin of 2.6% for the nine months ended September 30, 2025, compared to a net loss margin of 9.3% in 2024[31] - Cash provided by operating activities for the nine months ended September 30, 2025, was $65,655,000, an increase from $35,623,000 in 2024[28] - The company reported a diluted EPS of $0.45 for the nine months ended September 30, 2025, compared to a diluted loss per share of $2.00 in 2024[31] Guidance and Projections - The company raised its full-year revenue guidance to between $1.43 billion and $1.45 billion, up from the previous range of $1.39 billion to $1.41 billion[5] - Adjusted EBITDA guidance for the full year was increased to between $104.0 million and $106.0 million, up from $100.0 million to $102.0 million[5] Cash and Debt Position - Cash and cash equivalents totaled $36.5 million at quarter-end, with no long-term debt outstanding[7] - Total cash and cash equivalents at the end of the period were $36,487,000 for September 30, 2025, compared to $37,221,000 at the end of the previous year[28] Operational Developments - The acquisition of Managed Healthcare Pharmacy was announced, marking Guardian's first physical footprint in Oregon[8] - Guardian operates over 53 pharmacies nationwide, serving approximately 8,200 long-term care facilities across 38 states[10] - The company has filed a shelf registration statement for the potential issuance and resale of up to 5,000,000 shares of Class A common stock[9] Share-Based Compensation and Legal Matters - The company incurred share-based compensation expenses of $12,770,000 for the nine months ended September 30, 2025, down from $128,029,000 in 2024[28] - Proceeds from payor reimbursement matters recorded as revenue were $1.6 million for the three months ended September 30, 2025, compared to $0.0 million and $1.7 million for the same period in 2024[4] - Legal expenses related to payor reimbursement matters were $1.7 million and $2.8 million for the three and nine months ended September 30, 2025, respectively, while there were no expenses in the same periods of 2024[4] Adjusted Metrics - Adjusted net income and Adjusted EPS are not calculated for the three and nine months ended September 30, 2024, due to the limited net income attributable to Guardian Pharmacy Services, Inc. following the IPO[4]
Guardian Pharmacy Services, Inc.(GRDN) - 2025 Q3 - Quarterly Results